PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday, September 9, 2024, at 4:00 PM ET.
As part of the event, Pankaj Mohan, Founder and Chief Executive Officer of Sonnet BioTherapeutics, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event by emailing This email address is being protected from spambots. You need JavaScript enabled to view it.. Time permitting, the Company will respond to submitted questions.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.sonnetbio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
833-475-8247
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.49 |
| Daily Change: | -0.02 -1.52 |
| Daily Volume: | 45,341 |
| Market Cap: | US$4.480M |
December 17, 2024 December 09, 2024 December 09, 2024 November 06, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
